Nava Therapeutics
Founded 2022 · 37 employees on LinkedIn · 2 known investors
Nava develops lipid nanoparticles (LNPs) designed to deliver RNA therapeutics to specific organs and cellular targets for genetic medicine applications. The company focuses on addressing unmet medical needs across a range of RNA therapeutic treatments.
Founders & leadership
Nava Therapeutics was founded in 2022 by Curtis Dobrowolski.
CD
Curtis DobrowolskiinCo-Founder
Investors · 2
Competitors · 7
by search overlap
Orna8 shared keywordsOrna Therapeutics develops RNA and lipid nanoparticle (LNP) based therapies for treating diseases including oncology and cell therapy applications. The company leverages proprietary drug development expertise in oRNA and LNP technology platforms.
Abeona Therapeutics8 shared keywordsAbeona Therapeutics is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases with high unmet need, including its approved product ZEVASKYN and its lead PSMA-targeted T cell therapy ABO-701 for advanced prostate cancer. It uses ex vivo gene therapy, viral vector, and synthetic immune receptor T cell (SIR-T) technologies to serve patients with genetic diseases and solid tumors.
Navega Therapeutics8 shared keywordsNavega Therapeutics develops gene therapies using zinc-finger and CRISPR-based epigenome regulation to control gene expression. The company works in the biotech and gene therapy space.
Avernatx7 shared keywordsAverna Therapeutics is a biotechnology company developing therapeutics. The page is a team bio profiling its CEO and board member.
Neurona Therapeutics6 shared keywordsNeurona is a clinical-stage biotherapeutics company developing allogeneic, off-the-shelf regenerative neural cell therapies that integrate into neural circuits to treat chronic neurological disorders. Its pipeline includes neuronal, glial, and gene-edited cell therapy candidates led by NRTX-1001, an inhibitory neuron therapy for epilepsy.</parameter>
<parameter name="founders">[]
Sionnatx6 shared keywordsSionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs. It is advancing a portfolio of NBD1 stabilizers and complementary CFTR modulators intended to be used in combination to normalize CFTR function in CF patients.
ロゴマーク：AIRNA5 shared keywordsAIRNA develops RNA editing therapeutics aimed at providing functional cures for patients with rare diseases and common conditions. The company works in the genetic medicines and biotech space.
Companies competing with Nava Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Nava Therapeutics do?
- Nava develops lipid nanoparticles (LNPs) designed to deliver RNA therapeutics to specific organs and cellular targets for genetic medicine applications. The company focuses on addressing unmet medical needs across a range of RNA therapeutic treatments.
- Who founded Nava Therapeutics?
- Nava Therapeutics was founded by Curtis Dobrowolski in 2022.
- Who are Nava Therapeutics's investors?
- Nava Therapeutics's investors include Andreessen Horowitz, F-Prime Capital.